GlyProVac ApS
PrivateLast Round
Grant
Feb 29, 2024
Total Funding Raised
$2.01M
Company Overview
GlyProVac ApS operates in Healthcare & Life Sciences and is based in Odense. It has raised $2.01M.
GlyProVac ApS is a biotechnology company that develops bacterial subunit vaccines using its proprietary BEMAP technology to combat antimicrobial resistance.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
GlyProVac ApS Comparables
Compare GlyProVac ApS with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Proxi Biotech | 87% | |
| Omniose | 83% | |
| Syntiron | 81% |
For institutional investors. Book with your work email.
GlyProVac ApS Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
GlyProVac ApS Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovation Fund Denmark | Grant |
| CARB-X | Grant |
| Eurostars SME programme | Grant |
| Danish Agency for Higher Education and Science | Seed |
| Syddansk Innovation A/S | Corporate Funding, Seed |
| The Export and Investment Fund of Denmark | Corporate Funding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 29, 2024
$467K grant received from CARB-X.
For institutional investors. Book with your work email.
GlyProVac ApS Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about GlyProVac ApS's valuation, stock price, and market status.
Is GlyProVac ApS a public or private company?
GlyProVac ApS is a private company.
What is the current stock price of GlyProVac ApS?
GlyProVac ApS is a private company, so its shares have no public market price. Caplight tracks GlyProVac ApS's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is GlyProVac ApS worth (valuation)?
Valuation information for GlyProVac ApS is not publicly available.
Can I buy GlyProVac ApS stock?
GlyProVac ApS shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was GlyProVac ApS's last funding round?
GlyProVac ApS's most recent funding round was Grant on February 29, 2024.
Who are the main investors in GlyProVac ApS?
Key investors in GlyProVac ApS include Innovation Fund Denmark, CARB-X, Eurostars SME programme, Danish Agency for Higher Education and Science, Syddansk Innovation A/S.
Will GlyProVac ApS IPO soon?
No public IPO plans have been announced for GlyProVac ApS.
How can I track GlyProVac ApS secondary market activity?
Caplight tracks bids, offers, and trades in GlyProVac ApS's shares on secondary markets.